PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.21%
Both companies show declining cash positions (-13.21% vs TRVN's -28.40%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-13.21%
Below half of TRVN's -28.40%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.76%
Other current assets growth < half of TRVN's 36.08%. David Dodd sees a leaner approach to short-term items.
-11.17%
Below half of TRVN's -24.97%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
7.73%
Below half TRVN's -3.75%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Below half of TRVN's 0.41%. Michael Burry sees possible underinvestment in long-term assets. Verify capital constraints.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
7.08%
Below half of TRVN's -1.92%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.65%
Below half of TRVN's -21.34%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-100.00%
Above 1.5x TRVN's -29.85%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-100.00%
Less than half of TRVN's 3.00%. David Dodd sees much smaller short-term leverage burden vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both TRVN and the company show zero Deferred Revenue (Current) Growth.
1577.51%
Less than half of TRVN's -186.87%. David Dodd sees fewer expansions in other current obligations.
-26.01%
Above 1.5x TRVN's -8.17%. Michael Burry sees a red flag for liquidity risk vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
Higher Deferred Tax Liabilities (Non-Current) Growth compared to TRVN's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-0.35%
Less than half of TRVN's -17.37%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-6.06%
Less than half of TRVN's -14.94%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-3.82%
≥ 1.5x TRVN's -1.43%. David Dodd sees higher yoy retained profits than competitor.
100.00%
Less than half of TRVN's -100.00%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-13.95%
Below half TRVN's -34.91%. Michael Burry sees potential underperformance in building shareholder capital.
-10.65%
Below half TRVN's -21.34%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
-100.00%
Below half TRVN's 0.41%. Michael Burry suspects major underinvestment or forced divestment.
-4.69%
Above 1.5x TRVN's -0.86%. Michael Burry sees a major jump. Investigate leverage rationale.
13.42%
Less than half of TRVN's 57.75%. David Dodd sees better deleveraging or stronger cash buildup than competitor.